Top Page
Noxopharm Ltd.
(Sydney:NOX)
Noxopharm Ltd. (NOX) vs. iShares MSCI Australia ETF (EWA)
Noxopharm Ltd. Business Overview & Revenue Model
Noxopharm Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.82M | 2.82M | 2.40M | 6.01M | 5.43M | 5.61M |
| Gross Profit | -1.45M | -1.45M | -534.81K | 5.86M | 5.17M | 5.35M |
| EBITDA | -5.38M | -5.38M | -5.95M | -20.85M | -23.70M | -5.85M |
| Net Income | -4.88M | -4.88M | -3.58M | -15.06M | -18.67M | -9.35M |
Balance Sheet | ||||||
| Total Assets | 4.58M | 4.58M | 6.78M | 10.13M | 26.59M | 47.85M |
| Cash, Cash Equivalents and Short-Term Investments | 1.55M | 1.55M | 2.32M | 3.01M | 14.01M | 26.80M |
| Total Debt | 2.48M | 2.48M | 0.00 | 0.00 | 160.62K | 349.31K |
| Total Liabilities | 3.89M | 3.89M | 1.29M | 1.06M | 2.48M | 7.08M |
| Stockholders Equity | 689.96K | 689.96K | 5.50M | 9.07M | 24.12M | 40.78M |
Cash Flow | ||||||
| Free Cash Flow | -5.82M | -5.82M | -684.31K | -10.95M | -13.73M | -8.85M |
| Operating Cash Flow | -5.82M | -5.82M | -684.31K | -10.95M | -13.73M | -8.85M |
| Investing Cash Flow | 2.48M | 2.48M | 0.00 | 123.51K | 0.00 | 225.23K |
| Financing Cash Flow | 2.60M | 2.60M | 0.00 | -178.09K | 975.73K | 28.32M |
Noxopharm Ltd. Technical Analysis
Noxopharm Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$68.10M | 9.93 | 27.24% | 2.81% | 0.65% | -9.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$87.28M | -9.12 | -49.72% | ― | ― | 10.78% | |
46 Neutral | AU$27.47M | -5.63 | -157.93% | ― | ― | -36.89% | |
45 Neutral | AU$8.22M | -1.69 | -469.35% | ― | ― | 46.28% | |
44 Neutral | AU$193.03M | -7.40 | ― | ― | ― | 0.66% | |
44 Neutral | AU$111.71M | -13.68 | -47.98% | ― | 700.00% | 26.88% |
Noxopharm Ltd. Corporate Events
Noxopharm Ltd. has announced a change in the director’s interest, specifically involving Fred Bart, who has acquired 250,000 options and 1,250,000 convertible notes through 4F Investment Pty Limited. This change was approved by shareholders on November 18, 2025, and reflects a strategic move to enhance the company’s financial instruments, potentially impacting its market positioning and shareholder value.
Noxopharm Limited has issued 1,250,000 convertible notes and 250,000 unlisted options to 4F Investments Pty Limited, associated with a company director. This financial maneuver, involving a conversion of an unsecured loan into convertible notes, will not bring new cash inflow but will impact the company’s capital structure by potentially increasing the number of shares if the notes are converted. The move is designed to allow the resale of shares without disclosure to retail investors, potentially diluting existing shareholdings and altering the company’s equity distribution.
Noxopharm Ltd. has announced the issuance of unquoted equity securities, including 250,000 options expiring in 2027 and 1,250,000 convertible notes. This move is part of the company’s financial strategy to support its ongoing operations and growth in the oncology sector, potentially impacting its market position and stakeholder interests.
Noxopharm Limited announced the successful completion of the first multiple-dose cohort in the HERACLES clinical trial for SOF-SKN™, a novel drug candidate for autoimmune diseases like cutaneous lupus erythematosus. The trial, which is being conducted in Australia, aims to assess the safety and tolerability of SOF-SKN™ through repeated applications, reflecting real-world usage. The trial’s progression to the second and final cohort underscores the drug’s potential impact on the autoimmune disease therapeutics market, which is projected to grow significantly.
Noxopharm Limited announced that all resolutions were passed at its Annual General Meeting, with significant support for the adoption of the Remuneration Report. The company’s Sofra technology platform, which targets inflammatory and autoimmune diseases, holds potential for significant market impact, given the projected growth in the autoimmune disease therapeutics and immuno-oncology markets.
Noxopharm Limited has released its 2025 AGM Corporate Presentation, highlighting significant progress in its HERACLES clinical trial and the growing market opportunities for its Sofra™ technology in treating inflammation and cancer. The company has achieved a milestone with its first US patent grant and is gaining increased recognition and interest from third parties in its Sofra assets, positioning it well in the multi-billion dollar biotech market.
Noxopharm Limited’s 2025 AGM highlighted significant progress in advancing its Sofra™ technology platform, particularly with the SOF-SKN™ clinical trial in Australia. This advancement enhances the company’s reputation and attracts external stakeholder interest, evidenced by a US patent grant and support from the Victorian government. The company is well-positioned to capitalize on the growing interest in RNA technology and the rise in autoimmune diseases, while maintaining prudent operational spending and exploring funding opportunities.
Noxopharm Limited has commenced the second part of its HERACLES clinical trial, administering the first dose of SOF-SKN™, a novel drug candidate for autoimmune diseases like cutaneous lupus erythematosus. This phase aims to evaluate the safety and tolerability of SOF-SKN through repeated dosing, reflecting real-world conditions. The trial’s success could enhance Noxopharm’s position in the regulatory approval process and potentially expand the use of SOF-SKN to other autoimmune-related skin diseases, positioning the company to capture a share of the growing global cutaneous lupus market, valued at over US$3.3 billion.
Noxopharm Limited has announced a collaboration with UNSW Sydney, supported by a TechVoucher grant from the NSW Government, to conduct an early-stage feasibility study on their Sofra™ technology. This study aims to explore the potential of Noxopharm’s anti-inflammatory oligonucleotides to reduce inflammation caused by implants. The initiative highlights the versatility of the Sofra™ platform, which targets a wide range of inflammatory and autoimmune diseases, and underscores Noxopharm’s strategic partnerships to enhance its market positioning in the biotech industry.
Noxopharm Limited has commenced the second phase of its HERACLES clinical trial for SOF-SKN, a new drug candidate aimed at treating autoimmune diseases like cutaneous lupus erythematosus (CLE). The trial, which will test multiple ascending doses, aims to ensure the drug’s safety over repeated applications, potentially accelerating its development timeline by skipping the lowest dose cohorts. This advancement could position Noxopharm favorably within the growing global CLE market, valued at over US$3.3 billion, and further applications of the Sofra technology could extend to other autoimmune and inflammatory diseases.
Noxopharm Limited has reported significant progress in its September 2025 Quarterly Activities Report, highlighting new collaborations and promising trial results. The company has signed several collaboration agreements with institutions interested in its Sofra technology platform, which is being explored for various inflammatory diseases. A US company, Tezcat Biosciences, has shown promising preclinical results using Noxopharm’s oligonucleotides in a novel drug candidate. Additionally, Noxopharm’s HERACLES clinical trial has demonstrated that its SOF-SKN treatment is safe and well-tolerated, supporting the platform’s potential in treating autoimmune diseases. The extension of convertible notes and access to government rebates further strengthen the company’s financial position.
Noxopharm Limited has secured its first US patent for the Sofra™ technology platform, which is designed to harness immune-modulatory oligonucleotides for cancer treatment. This patent protects the structure of Noxopharm’s assets, ensuring the commercial value of their ongoing cancer research. The Sofra platform, developed in collaboration with the Hudson Institute of Medical Research, shows potential for versatile applications in mitigating inflammation and weaponizing the immune system against cancer. This milestone positions Noxopharm favorably in the growing immuno-oncology market, projected to expand significantly in the coming years.
Noxopharm Limited has announced its 2025 Annual General Meeting (AGM) will be held as a physical meeting on November 18, 2025, in Sydney. The AGM will address several key resolutions, including the adoption of the remuneration report, re-election of a director, and approval of future securities issues and incentive plans. This meeting is crucial for stakeholders as it outlines the company’s strategic plans and governance decisions, impacting its market positioning and operational focus.
Noxopharm Limited has released its Annual Report for the year ending June 30, 2025, highlighting significant progress in its clinical trials and growing interest in its Sofra™ technology platform. The company has successfully advanced its first asset, SOF-SKN™, from preclinical studies to clinical trials, demonstrating its ability to quickly translate research into real-world applications. This milestone has attracted considerable external stakeholder interest, enhancing Noxopharm’s industry positioning and potential impact on cancer and inflammation treatment.
Noxopharm Limited has released its Appendix 4G and Corporate Governance Statement for FY2025, highlighting its commitment to transparency and adherence to ASX governance standards. This announcement underscores the company’s dedication to maintaining robust corporate governance practices, which is crucial for its stakeholders and enhances its positioning within the biotech industry.